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De Novo Small Vessel Coronary Disease: To Stent Or Not To Stent? Can
Drug Coated Balloon Be A Safe And Effective Alternative To Modern Drug
Eluting Stent?
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BACKGROUND Percutaneous coronary intervention (PCI) with drug
eluting stent (DES) in small vessel coronary disease
(diameter <2.8 mm) has been proved superior to plain balloon an-
gioplasty or bare metal stent with lower target lesion revasculariza-
tion (TLR) rate. Drug coated balloon (DCB) has been used to treat
de-novo small vessel coronary disease (SVD) with promising result
and shorter dual antiplatelet therapy (DAPT) duration. The purpose of
the study is to compare the safety and effectiveness of DCB in de novo
SVD compared to second generation DES at 1 year.
METHODS We reviewed 3613 angioplasty cases retrospectively from
2011 to 2013 and identiﬁed 335 patients with SVD treated with device
diameter  2.5 mm. 172 were treated with DCB only (paclitaxel-pac-
cocath) and 163 patients treated with second generation DES (ever-
olimus 33.7%, zotarolimus 33.7% and biolimus 32.5%) with clinical
follow up at 12 months.
RESULTS There was no difference in gender (male 76.7% vs 71.8%,
p ¼ 0.32), age (mean 61.0 vs 61.2, p ¼ 0.35), incidence of diabetes
(51.2% vs 49.1%, p ¼ 0.74), hypertension (72.7% vs 69.3%, p ¼ 0.55),
hyperlipidemia (69.8% vs 72.4, p ¼ 0.63), and smoker (45.4% vs
46.6%, p ¼ 0.83). DCB patients had smaller reference vessel diameter
(2.22  0.29 vs 2.43  0.19 mm, p < 0.001), and received smaller de-
vices (diameter 2.28  0.21 vs 2.38  0.12 mm, p < 0.001; length 20.2 
6.0 vs 22.2  7.2 mm, p < 0.005) compared to the DES group. There
was no signiﬁcant difference on number of devices used (1.37  0.6 vs
1.39  0.7, p ¼ 0.25) or the distribution of type C lesion (42.44% vs
37.79%, p ¼ 0.66) between the DCB and DES arms. There was a trend
towards larger acute lumen gain in the DES treated vessels (1.70 
0.48 mm) compared to DCB (1.00  0.53, p ¼ 0.09). There were more
patients presenting with acute coronary syndrome (ACS) in the DCB
group (77.9% vs 62.2%, p < 0.005). Despite that, patients treated with
DCB received shorter duration of dual antiplatelet therapy (DAPT; 7.4
 4.7 months vs 11.8  1.4 months, p < 0.001). Cumulative one-year
events showed no difference in composite major adverse cardiac
events (MACE) (11.6% vs 11.7%), p ¼ 1.00), death (1.7% vs 3.7%, p ¼
0.33), myocardial infarction (5.8% vs 8.6%, p ¼ 0.40), target lesion
revascularization (5.2% vs 3.68%, p ¼ 0.60) and stroke events (1.16%
vs 0.61%, p ¼ 1.00) between the DCB and DES arms respectively.
Univariate, followed by multivariate cox-regression analysis to all risk
factors and lesion characteristics revealed type C lesion as the only
independent predictor of 1-year composite MACE (RR 2.52, p
value < 0.05).
CONCLUSIONS In this high risk cohort of patients (>50% diabetics,
78% ACS) DCB only angioplasty delivered good clinical outcome at 1
year. The result was comparable to those treated with modern DES but
has the added beneﬁt of a shorter DAPT regime.
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BACKGROUND Second-generation drug-coated balloons (DCB) may
be an alternative to stents in selected populations for the treatment of
native coronary lesions. However, the use of these devices may be
hampered by a certain risk of acute vessel recoil or residual coronary
dissection. Moreover, stenting after DCB has limited scientiﬁc evi-
dence. Little is known when a not ﬂow-limiting dissection is left after
DCB-angioplasty.
METHODS This was a prospective observational study whose aim was
to investigate the outcome of a consecutive series of patients with
native coronary artery disease treated with second-generation DCB
and residual coronary dissection at two Italian centers. We evaluated
patient clinical conditions at 1 and 9 months and angiographic follow
up was undertaken at 6 months.RESULTS Between July 2012 and July 2014, 156 patients were treated
with DCB for native coronary artery disease. Fifty-two patients had a
ﬁnal dissection, 4 of which underwent prosthesis implantation and 48
were left untreated and underwent angiographic follow up after 201
days (I.Q. range: 161-250 days). The dissections were all type A-C and
none determined an impaired distal ﬂow. Complete vessel healing at
angiography was observed in 45 patients (93.8%), whereas 3 patients
had persistent but uncomplicated dissections, and 3 binary restenosis
(6.2%). Late-lumen-loss was 0.14mm (-0.14-0.42). Major adverse car-
diovascular events occurred in 11 patients of the entire cohort and in 4
of the dissection cohort (7.2% vs. 8.1%, p¼0.48). We observed 8 and 3
target-lesion revascularizations respectively (5.3% vs. 6.2%, p¼0.37).
CONCLUSIONS In this cohort of consecutive patients treated with
new-generation DCB and left with a ﬁnal dissection, this strategy of
revascularization seemed associated with the sealing of most of dis-
sections and without signiﬁcant neo-intimal hyperplasia.
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BACKGROUND Drug eluting balloons currently constitute one of the
therapeutic tools used in percutaneous coronary intervention (PCI) of
de novo coronary lesions, mainly in bifurcations and small vessels.
Nowadays, their results at a very long-term follow up are unclear. The
main objective of this study was to evaluate the efﬁcacy and safety of
second-generation Sequent Please paclitaxel eluting balloon (PEB) in
de novo coronary lesions at 6 years.
METHODS We prospectively included 87 consecutive patients (6912
years, 66.7% male) with 87 de novo lesions treated with PEB between
March 2009 and January 2014. Additional bare metal stent (BMS) or
drug-eluting stent (DES) was implanted after PEB if the result was not
satisfactory because of dissection, recoil or signiﬁcant residual ste-
nosis. We evaluated the presence of major cardiac events (MACE) after
a prolonged clinical follow-up (median 51 months): death, nonfatal
myocardial infarction, target lesion revascularization (TLR) and
thrombosis.
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68.9% acute coronary syndromes (49.4% Non-STEMI and 19.5%
STEMI). 46% of patients were diabetic. 48.3% of lesions were bi-
furcations, 17.2% diffuse and 52.8% type B2/C. Mean vessel diameter
and length were 2.43  0.35 mm and 16.03  5.6 mm, respectively. 77
% of the lesions were treated with PEB, 19.5% with PEB and BMS and
3.4% with PEB and DES. There were no signiﬁcant differences
regarding baseline characteristics of these three groups neither in the
MACE rate after a long-term follow-up (p¼0.5). During follow-up, 6
patients died (1 cardiovascular and 5 non-cardiovascular deaths) and a
TLR rate of 2.3% was observed. Two cases of non-fatal myocardial
infarction (2.3%) and no cases of thrombosis were observed, imme-
diately after the procedure nor during follow-up. 16.1% of patients had
angiographic follow-up. We did not observe a higher need for addi-
tional stent after PEB in complex lesions such as diffuse lesions
(p¼0.7) and bifurcations (p¼0.7). However a higher MACE rate at 5
years was observed in bifurcations and ostial lesions.
CONCLUSIONS Percutaneous interventions of “De Novo” coronary
lesions with Sequent Please PEB offers very favorable results at a
very long-term follow up. There was not a higher need for additional
stent in cases of diffuse and bifurcated lesions.
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BACKGROUND Drug eluting balloons currently constitute one of the
therapeutic tools used in percutaneous coronary intervention (PCI) of
both stent restenosis and “De Novo” coronary lesions, mainly in bi-
furcations and small vessels. Diabetic patients represent an unfavor-
able subgroup because of their higher restenosis and adverse events
rates. Nowadays, the results at a very long-term follow up are unclear
in this subset of patients. The main objective of this study was to
evaluate the efﬁcacy and safety of second-generation Sequent Please
paclitaxel eluting balloon (PEB) at 6 years in diabetics.
METHODS We prospectively included 111 consecutive diabetic pa-
tients (6912 years, 64% male) with 111 lesions (de novo or restenosis)
treated with PEB between March 2009 and January 2014. We evalu-
ated the presence of major cardiac events (MACE) after a prolonged
clinical follow-up (median 47 months): death, nonfatal myocardial
infarction, target lesion revascularization (TLR) and thrombosis.
RESULTS 44.2% of patients had stable coronary artery disease and
55.8% acute coronary syndromes (45% Non-STEMI and 10.8% STEMI).
20.7% of lesions were bifurcations. Of the 111 lesions, 36.1% were “De
Novo” lesions and 63.9% restenosis [37.8% restenosis of bare metal
stent (BMS) and 26.1% of drug-eluting stents (DES)]. 88.3% of the le-
sions were treated with PEB, 8.1% with PEB and BMS and 3.6% with
PEB and DES. There were no signiﬁcant differences regarding baseline
characteristics of these three groups neither in the MACE rate after a
long-term follow-up (p¼0.8). During follow-up, 9 patients died (3
cardiovascular and 6 non-cardiovascular deaths), and a TLR rate of
3.6% and two non-fatal myocardial infarction rate of 1.8% were
observed. No cases of thrombosis were observed, immediately after
the procedure nor during follow-up. 19.8% of patients had an angio-
graphic follow-up. Bifurcated lesions presented a higher rate of
dissection after PEB (p¼0.016) and a higher need of additional stent
(p¼0.025).
CONCLUSIONS In diabetic patients, percutaneous coronary inter-
vention of de novo coronary lesions and in-stent restenosis (both of
BMS and DES) with Sequent Please PEB provide very favorable re-
sults at a very long-term follow up. Bifurcated lesions presented a
higher rate of dissection after PEB and a higher need of additional
stent.
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BACKGROUND There has been much interest in the use of paclitaxel
coated balloon (PCB) only angioplasty in de novo coronary lesions. In
certain clinical situations such as bifurcation, recoil or major dissec-
tion after PCB deployment an additional stent may be implanted to
support vessel patency. The consensus opinion is to use a bare metal
stent (BMS) instead of a drug eluting stent to cover the PCB treated
segment. This may avoid the unknown effect of combining paclitaxel
with a limus agent. We designed a porcine model to compare the
angiographic and optical coherence tomography (OCT) ﬁndings of
implanting an everolimus eluting stent (EES) in the same segment of
the coronary artery pre-treated with a PCB (paccocath as carrier) with
EES alone and PCB plus BMS.
METHODS 7 female swine averaging 46.02.4 kg were studied. Under
general anesthetic, the 3 coronary arteries of each animal were randomly
implantedwith 1. PCB (3.0 by 15mm) followed by EES (3.0 by 8mm); 2. PCB
(3.0 by 15mm) followed by BMS (3.0 by 8mm) and 3. EES (3.0 by 8mm)
alone. Quantitative coronary angiography (QCA) and OCTwere carried out
post implantation. QCA and OCT were repeated after 281 days.
RESULTS All arteries remained patent and demonstrated no sign of
thrombus formation on angiogramorOCT. Thewas nodifference in lumen
loss at 1 month between the 3 treatment groups (0.520.36mm,
0.450.44mm and 0.300.24mm for EES, PCBþEES and PCBþBMS
respectively, p¼0.54). There was no difference in diameter stenosis at 1
month (8.7111.88%, 4.1412.97% and 4.807.65% for EES, PCBþEES and
PCBþBMS respectively, p¼0.71). The mean endothelial area measured by
OCT at 1 month were 1.580.83mm2, 0.950.19mm2 and 0.970.23mm2
for EES, PCBþEES and PCBþBMS respectively, p¼0.064.
CONCLUSIONS The combination of PCB with EES appeared to be safe
and effective compared to EES alone. There is a trend to suggest the
combination of PCB with EES may be more effective in suppressing
neointimal hyperplasia than using EES as observed in the lower
endothelial area measurement. Using EES to bail out suboptimal PCB
therapy appeared to be safe and effective in the porcine model.
Further histological analysis and larger cohort may provide more in-
formation on this treatment strategy.
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